<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1089">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146973</url>
  </required_header>
  <id_info>
    <org_study_id>ProstACT TARGET</org_study_id>
    <nct_id>NCT05146973</nct_id>
  </id_info>
  <brief_title>External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)</brief_title>
  <official_title>A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telix International Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telix International Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled&#xD;
      PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation&#xD;
      therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing&#xD;
      prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled&#xD;
      with a therapeutic radiosotope for the treatment of PSMA-expressing tumours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine Prostate Specific Antigen Progression Free Survival (PSA PFS)</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>The time from enrolment to time of PSA increase greater than 25%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single administration of 177Lu-DOTA-TLX591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>177Lu-DOTA-TLX591</intervention_name>
    <description>TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)</description>
    <arm_group_label>Single administration of 177Lu-DOTA-TLX591</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Male, aged ≥ 18 years&#xD;
&#xD;
          -  Estimated life expectancy of at least 6 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score 0 - 2&#xD;
&#xD;
          -  Biopsy proven prostate adenocarcinoma with Gleason Score 7 or more at primary&#xD;
             presentation&#xD;
&#xD;
          -  Previous Radical Prostatectomy (RP) with curative intent (+/- post-operative&#xD;
             radiotherapy to prostate bed)&#xD;
&#xD;
          -  Biochemical relapse, as defined by EAU-ESTRO-SIOG Guidelines (serum PSA &gt; 0.2 ng/mL,&#xD;
             confirmed by repeat measurements)&#xD;
&#xD;
          -  PSMA-ligand avid pelvic nodal disease on PSMA-ligand PET/CT, with visualised disease&#xD;
             confined to the pelvis with or without evidence of PSMA-avid disease in the prostate&#xD;
             bed&#xD;
&#xD;
          -  At least one pelvic nodal lesion ≥ 5 mm in the greatest dimension. SUVmax &gt; 9 in&#xD;
             enlarged nodes; SUVmax &gt; 3 in nodes 5 mm or less&#xD;
&#xD;
          -  Oligometastatic disease as defined by ≤ 5 metastatic lymph nodes&#xD;
&#xD;
          -  Metastatic lymph nodes not beyond the aortic bifurcation&#xD;
&#xD;
          -  Non-castrate levels of testosterone (&gt; 20 ng/dL)&#xD;
&#xD;
          -  Chemotherapy naïve&#xD;
&#xD;
          -  Adequate renal function: Cr Cl ≥ 40 mL/min (determined by Cockcroft-Gault formula)&#xD;
&#xD;
          -  Adequate bone marrow function: Hb &gt; 90 g/L; platelets &gt; 100 x 109/L; neutrophils &gt; 1.5&#xD;
             x 109/L&#xD;
&#xD;
          -  Adequate liver function: bilirubin &lt; 1.5 x upper limit of normal (ULN); AST, ALT, ALP&#xD;
             &lt; 2 x ULN; albumin &gt; 30 g/L&#xD;
&#xD;
          -  Willing and able to comply with all trial requirements, including all treatments and&#xD;
             pre- and post-treatment assessments&#xD;
&#xD;
          -  Able to commence treatment within 28 days of enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous external beam radiotherapy to pelvis for other malignancies or medical&#xD;
             conditions (except for post-operative prostate bed radiotherapy for prostate cancer)&#xD;
&#xD;
          -  Androgen deprivation therapy within 12 months of trial screening&#xD;
&#xD;
          -  Known androgen deficiency&#xD;
&#xD;
          -  Bone or visceral metastases&#xD;
&#xD;
          -  Lymph node metastases above the aortic bifurcation&#xD;
&#xD;
          -  Contraindications to pelvic irradiation as determined by Investigator (e.g., chronic&#xD;
             inflammatory bowel disease)&#xD;
&#xD;
          -  At increased risk of haemorrhage, or recent history of a thrombotic event (e.g., Deep&#xD;
             Vein Thrombosis [DVT]/Pulmonary Embolism [PE]) and/or are using long-term&#xD;
             anti-coagulant or anti-platelet agents)&#xD;
&#xD;
          -  Known hypersensitivity to any isotope of lutetium (Lu) in any chemical form, or any&#xD;
             isotope used in PSMA imaging&#xD;
&#xD;
          -  Contraindication to intravenous contrast&#xD;
&#xD;
          -  Evidence of urinary tract stricture, or significant urinary/faecal incontinence&#xD;
             Presence of active infection at time of screening, or history of serious infection&#xD;
             within the previous 4 weeks&#xD;
&#xD;
          -  History of any malignancy other than prostate cancer within 5 years of enrolment&#xD;
             (excluding localised non-melanoma skin cancers)&#xD;
&#xD;
          -  Any uncontrolled significant medical, psychiatric, or surgical condition (e.g., active&#xD;
             infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled type 2&#xD;
             diabetes, uncontrolled congestive heart failure, pulmonary disease), or laboratory&#xD;
             findings that, in the opinion of the Investigator, may jeopardise the participant's&#xD;
             safety or that would limit compliance with the treatment and assessment requirements&#xD;
             of the trial&#xD;
&#xD;
          -  Any cognitive impairment or other condition that may render the participant unable to&#xD;
             adequately understand the requirements, nature, and possible consequences of the&#xD;
             trial.&#xD;
&#xD;
          -  Intention to father children within a timeframe corresponding with the duration of the&#xD;
             allocated treatment regime plus 12 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darryl Carrington</last_name>
    <phone>+61411613226</phone>
    <email>darryl.carrington@telixpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori Lombardo</last_name>
    <phone>+1 610 213 0262</phone>
    <email>lori.lombardo@genesiscare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GenesisCare North Shore</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence Krieger</last_name>
      <email>laurence_krieger@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenesisCare Murdoch</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Nat Lenzo, MD</last_name>
      <phone>+61 02 8236 3300</phone>
      <email>nat.lenzo@genesiscare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>December 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 5, 2021</last_update_submitted>
  <last_update_submitted_qc>December 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

